What Matters to Patients: Metabolic Health Beyond Weight Loss

Published: 06 July 2023

  • Views:

    Views Icon 21728
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating
Download Slides

Overview

Radcliffe Medical Education bring together a distinguished panel of globally renowned experts who provide guidance on navigating the ever-changing landscape of obesity and metabolic health management. 

 

Under the chairmanship of Prof Jason Halford (University of Leeds, UK), the panel including Dr Lee Kaplan (Obesity, Metabolism and Nutrition Institute, Massachusetts General Hospital, US), Dr Fatima Cody Stanford (Massachusetts General Hospital, US) and Prof Filip Knop (University of Copenhagen, DK) explore the pressing unmet needs in obesity management. The panel discuss how to leverage patient-reported outcomes to improve care, unveil emerging clinical and pre-clinical data and chart the course for future strategies in this critical field. Gain access to the forefront of metabolic health management, empowering you to make informed decisions and shape the future of patient care.

 

Susie Birney, representing the European Coalition for People Living with Obesity (ECPO) from Dublin, IE, provides invaluable insights from a patient advocacy standpoint, emphasising the importance of patient-reported outcomes. Her insights shed light on the lived experiences of individuals with obesity and the importance of incorporating patient-reported outcomes in the management of obesity and metabolic health.

 

Presented, and recorded, at ECO 2023 in Dublin, IE.

EASO 23 IME Symposium: What Matters to Patients: Metabolic Health Beyond Weight Loss’ program: Boehringer Ingelheim (BI) has provided funding for this program. BI has had no input into the agenda, presentations or collateral content. Radcliffe Medical retains full and sole editorial control. It is not intended for healthcare professionals based in the UK or Ireland.

Key Learning Objectives

  • Describe the global incidence of obesity and limitations of existing pharmacological approaches
  • Recall pre-clinical data for emerging dual GLP-1/GCGR agonists in obesity
  • Recall clinical and safety data from dual GLP-1/GCGR agonists in obesity
  • Discuss the potential clinical impact of novel obesity agents
  • Describe a standardised approach toward patient reported outcomes in obesity

Target Audience

  • Endocrinologists
  • Diabetologists
  • Cardiologists
  • Primary Care Physicians
  • Any other allied HCPs

More from this programme

Part 1

Obesity and Current Unmet Needs

Dr Fatima Cody Stanford opens this symposium by examining the current obesity burden, estimated worldwide prevalence and avoidable fatalities. Additionally, she explores the historical context of obesity treatments and highlights the potential of anti-obesity medications, along with lifestyle interventions, in managing this chronic disease.

Part 2

Patient Reported Outcomes

During this session, Susie Birney provides a valuable patient's perspective on obesity. She highlights the significance of patient-reported outcome measures (PROMs) in understanding the experiences and needs of individuals living with obesity, drawing from her own personal journey.

Part 3

The Concept of Mono, Dual & Triple Agonists

Dr Lee Kaplan takes the stage to explore the concept of mono, dual, and triple agonists and their implications in the field of obesity medicine. He delves into the design and potential benefits of these therapeutic approaches for managing obesity.

Part 4

Emerging Clinical Data in GCGR/GLP-1R Agonism

During this session, Prof Filip Knop provides an overview of emerging clinical data related to future therapies for obesity. He focuses on efficacy and safety information obtained from phase 1 and 2 trials, shedding light on the potential of these therapies.

Part 5

How will Emerging Data and PROs Impact Obesity Management?

The panel concludes the symposium with an engaging discussion focusing on the influence of emerging clinical data and patient-reported outcomes (PROs) on obesity management, while also addressing questions from the audience. 

Faculty Biographies

Jason Halford

Jason Halford

Head of the School of Psychology

Prof Jason Halford is Head of the School of Psychology at the University of Leeds, and President of the European Association for the Study of Obesity (EASO). His research has focused on eating behaviour and weight management, and the role of psychological factors in weight gain and weight loss, with a recent focus on stress and coping.

View full profile
Fatima Cody Stanford Cody Stanford

Fatima Cody Stanford Cody Stanford

Associate Professor of Medicine and Pediatrics

Dr Fatima Cody Stanford is an obesity medicine physician scientist, educator, and policy maker at Massachusetts General Hospital and Harvard Medical School in Boston, US. She is a national and international sought after expert in obesity medicine who bridges the intersection of medicine, public health, policy, and disparities.

View full profile
Lee  Kaplan

Lee Kaplan

Director of the Obesity, Metabolism & Nutrition Institute

Dr Lee Kaplan is Director of the Obesity, Metabolism & Nutrition Institute, founding director of the Weight Center at the Massachusetts General Hospital, and associate professor of medicine at Harvard Medical School. 

Dr Kaplan's clinical expertise is in the areas of obesity medicine, gastroenterology and liver disease. The author of more than 150 medical and scientific papers, he has a special interest in the causes and complications of obesity and the development of new and more effective preventive strategies and therapies for this problem. His clinical research is focused on identifying clinically relevant subtypes of obesity, identifying predictors of outcome of obesity therapies, and exploring novel, combination therapies for obesity and its complications. 

View full profile
Filip Knop

Filip Knop

Director of Center for Clinical Metabolic Research

Prof Filip Knop is Director of Center for Clinical Metabolic Research at the Gentofte Hospital in Copenhagen, and Professor of Endocrinology, Department of Clinical Medicine, Faculty of Health and Medical Sciences at the University of Copenhagen, Denmark. 

His research, for which he has received a number of grants and honors (e.g. named “Rising star” by the European Association for the Study of Diabetes), centers on the pathophysiology of type 2 diabetes, obesity, regulation of appetite and food intake, and the therapeutic role of incretins. He is particularly interested in the integrative role of the gut in human (patho)physiology and has authored more than 220 scientific publications. He serves as a referee for several international journals including The Lancet, British Medical Journal, Diabetes, and Diabetologia and he is a member of numerous professional societies and committees.

 

View full profile
Susie Birney

Susie Birney

Advocate for Obesity; EPCO Secretary

Susie Birney lives with a food disorder called ARFID; she understands that there is not only one cause for obesity and not one treatment which will always work. Type 2 Diabetes and other co-morbidities have been health barriers for her since her 30’s. Since 2016, Susie has been a patient representative with the ASOI and an Irish representative with ECPO. This led to the start of creating a national patient led organisation ICPO from 2018. She shares her experiences to help to improve the lives of those who live with obesity.

View full profile

Comments

You must be to comment. If you are not registered, you can register here.